Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more
Aura Biosciences Inc (AURA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.129x
Based on the latest financial reports, Aura Biosciences Inc (AURA) has a cash flow conversion efficiency ratio of -0.129x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.14 Million) by net assets ($156.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aura Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Aura Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aura Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aura Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vista Gold Corporation
NYSE MKT:VGZ
|
-0.036x |
|
Eve Holding Inc
NYSE:EVEX
|
-0.293x |
|
Wajax Corporation
PINK:WJXFF
|
0.026x |
|
OCUMENSION THER.DL-00001
F:5DG
|
N/A |
|
ALGOMA CENTRL CORP. CD 2
F:ACH
|
N/A |
|
AUCTION TECH.GRP.LS-0001
F:684
|
N/A |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
-0.058x |
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
N/A |
Annual Cash Flow Conversion Efficiency for Aura Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Aura Biosciences Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $151.97 Million | $-79.81 Million | -0.525x | -85.76% |
| 2023-12-31 | $225.85 Million | $-63.85 Million | -0.283x | -1.26% |
| 2022-12-31 | $195.58 Million | $-54.60 Million | -0.279x | -31.20% |
| 2021-12-31 | $152.31 Million | $-32.41 Million | -0.213x | +83.06% |
| 2020-12-31 | $19.36 Million | $-24.32 Million | -1.256x | -86.97% |
| 2019-12-31 | $30.76 Million | $-20.67 Million | -0.672x | -- |